Phase 2 Study of WGI-0301 for Advanced HCC

NCT06309485 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

DRUG: WGI-0301 at MTD/RP2D dose IV infusion, QW
DRUG: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW
DRUG: Sorafenib 400 mg PO, BID continuously
DRUG: Sorafenib 400 mg PO, BID

Sponsor

Zhejiang Haichang Biotech Co., Ltd.